DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer

被引：0
|
作者：
Varun Sasidharan Nair
Salman M. Toor
Rowaida Z. Taha
Hibah Shaath
Eyad Elkord
机构：
[1] Qatar Foundation,Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University
[2] Institute of Cancer Sciences,undefined
[3] University of Manchester,undefined
来源：
Clinical Epigenetics | 2018年 / 10卷
关键词：
Colorectal cancer; Immune checkpoints; PD-L1; Galectin-9; DNA methylation; Histone trimethylation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma
    Sorkhabi, Amin Daei
    Sarkesh, Aila
    Fotouhi, Ali
    Saeedi, Hossein
    Aghebati-Maleki, Leili
    IUBMB LIFE, 2022, 74 (09) : 908 - 917
  • [32] The impact of PD-1/PD-L1, CTLA-4, TIM-3 and LAG-3 immune checkpoint receptor expression in the development of acute graft versus host disease (aGVHD) and disease recurrence after allogeneic hematopoietic stem cell transplantation
    Ramzi, Mani
    Dehghani, Mehdi
    Hajimaghsoodi, Maryam
    Golmoghaddam, Hossein
    Arandi, Nargess
    HUMAN IMMUNOLOGY, 2025, 86 (01)
  • [33] Serum Concentrations of TIM-3, LAG-3, and PD-1 in Patients with Hemorrhagic Fever with Renal Syndrome
    Safranko, Zeljka Macak
    Jakopec, Lana
    Svagusa, Karla
    Krajinovic, Lidija Cvetko
    Tomasovic, Domagoj
    Lukic, Ljiljana
    Markotic, Alemka
    LIFE-BASEL, 2024, 14 (05):
  • [34] Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
    Bruss, Christina
    Kellner, Kerstin
    Albert, Veruschka
    Hutchinson, James A.
    Seitz, Stephan
    Ortmann, Olaf
    Brockhoff, Gero
    Wege, Anja K.
    CANCERS, 2023, 15 (09)
  • [35] The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
    Andrea De Giglio
    Alessandro Di Federico
    Giacomo Nuvola
    Chiara Deiana
    Francesco Gelsomino
    Current Oncology Reports, 2021, 23
  • [36] The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
    De Giglio, Andrea
    Di Federico, Alessandro
    Nuvola, Giacomo
    Deiana, Chiara
    Gelsomino, Francesco
    CURRENT ONCOLOGY REPORTS, 2021, 23 (11)
  • [37] Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
    Limagne, Emeric
    Richard, Corentin
    Thibaudin, Marion
    Fumet, Jean-David
    Truntzer, Caroline
    Lagrange, Aurelie
    Favier, Laure
    Coudert, Bruno
    Ghiringhelli, Francois
    ONCOIMMUNOLOGY, 2019, 8 (04):
  • [38] PD-L1, PD-1, and CTLA-4 Expression in Invasive Breast Cancer in Young Women
    Obeidin, Farres
    Pincus, Jennifer
    Siziopikou, K. P.
    Blanco, Luis
    LABORATORY INVESTIGATION, 2019, 99
  • [39] Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
    Cheng, Weishi
    Kang, Kai
    Zhao, Ailin
    Wu, Yijun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [40] PD-L1, PD-1, and CTLA-4 Expression in Invasive Breast Cancer in Young Women
    Obeidin, Farres
    Pincus, Jennifer
    Siziopikou, K. P.
    Blanco, Luis
    MODERN PATHOLOGY, 2019, 32
12345